BPI-572270 / Betta Pharma - LARVOL DELTA

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

First-in-human, phase I/II study of BPI-572270, an oral RAS(ON) multi tri-complex inhibitor, in patients with RAS-mutated advanced solid tumors (AACR 2026) - "The study has been initiated with anticipated first patient dosing in the first quarter 2026."

Clinical • First-in-human • Metastases • P1/2 data • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS • NRAS

BPI-572270: An orally bioavailable and highly potent RAS (On) multi tri-complex inhibitor (AACR 2025) - "Safety evaluations in repeated-dose studies in rats and beagle dogs indicate a promising safety profile, reinforcing its potential for further clinical development. In conclusion, BPI-572270 emerges as a highly potent, orally bioavailable RAS(On)multi inhibitor, with favorable efficacy, pharmacokinetics, and safety profiles in pre-clinical studies."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS • NRAS

Study of BPI-572070 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd.

New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor